Key Points
- Director Floyd Petersen sold 1,737 shares on Dec. 11 at an average price of $25.69 for total proceeds of $44,623.53, reducing his stake by 2.3% to 73,794 shares — the sale was disclosed in an SEC Form 4 filing.
- Amphastar posted a quarterly beat with $0.93 EPS vs. a $0.83 consensus and revenue of $191.84 million, and reported a net margin of 15.43% and ROE of 19.70%.
- The stock has a market cap of $1.21 billion and a P/E of 11.64, and analysts hold a consensus rating of "Hold" with a $31.00 average price target (two Buy, six Hold).
Amphastar Pharmaceuticals, Inc. (NASDAQ:AMPH - Get Free Report) Director Floyd Petersen sold 1,737 shares of the business's stock in a transaction on Thursday, December 11th. The stock was sold at an average price of $25.69, for a total value of $44,623.53. Following the transaction, the director owned 73,794 shares in the company, valued at approximately $1,895,767.86. This trade represents a 2.30% decrease in their ownership of the stock. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through the SEC website.
Amphastar Pharmaceuticals Trading Up 4.1%
Amphastar Pharmaceuticals stock opened at $26.31 on Tuesday. The company has a debt-to-equity ratio of 0.78, a quick ratio of 2.21 and a current ratio of 3.12. The stock has a market cap of $1.21 billion, a PE ratio of 11.64, a price-to-earnings-growth ratio of 7.08 and a beta of 0.91. The stock has a 50-day moving average of $25.52 and a two-hundred day moving average of $25.66. Amphastar Pharmaceuticals, Inc. has a one year low of $20.39 and a one year high of $42.49.
Amphastar Pharmaceuticals (NASDAQ:AMPH - Get Free Report) last posted its quarterly earnings data on Thursday, November 6th. The company reported $0.93 earnings per share (EPS) for the quarter, beating the consensus estimate of $0.83 by $0.10. The firm had revenue of $191.84 million for the quarter, compared to the consensus estimate of $186.90 million. Amphastar Pharmaceuticals had a net margin of 15.43% and a return on equity of 19.70%. On average, research analysts anticipate that Amphastar Pharmaceuticals, Inc. will post 3.49 EPS for the current fiscal year.
Hedge Funds Weigh In On Amphastar Pharmaceuticals
Hedge funds have recently bought and sold shares of the business. Farther Finance Advisors LLC grew its holdings in Amphastar Pharmaceuticals by 356.0% in the third quarter. Farther Finance Advisors LLC now owns 944 shares of the company's stock valued at $25,000 after purchasing an additional 737 shares during the period. FNY Investment Advisers LLC purchased a new position in shares of Amphastar Pharmaceuticals during the 3rd quarter valued at approximately $26,000. Global Retirement Partners LLC grew its stake in Amphastar Pharmaceuticals by 219.0% in the 3rd quarter. Global Retirement Partners LLC now owns 1,024 shares of the company's stock valued at $27,000 after acquiring an additional 703 shares during the period. MassMutual Private Wealth & Trust FSB increased its holdings in Amphastar Pharmaceuticals by 192.8% in the 2nd quarter. MassMutual Private Wealth & Trust FSB now owns 1,262 shares of the company's stock worth $29,000 after acquiring an additional 831 shares in the last quarter. Finally, Hantz Financial Services Inc. raised its position in Amphastar Pharmaceuticals by 3,430.8% during the second quarter. Hantz Financial Services Inc. now owns 1,377 shares of the company's stock worth $32,000 after acquiring an additional 1,338 shares during the period. Hedge funds and other institutional investors own 65.09% of the company's stock.
Wall Street Analyst Weigh In
Several research firms recently issued reports on AMPH. Needham & Company LLC cut their target price on Amphastar Pharmaceuticals from $36.00 to $34.00 and set a "buy" rating on the stock in a research report on Friday, November 7th. Barclays began coverage on Amphastar Pharmaceuticals in a report on Tuesday, December 9th. They issued an "equal weight" rating and a $30.00 price objective on the stock. Weiss Ratings reissued a "hold (c)" rating on shares of Amphastar Pharmaceuticals in a research report on Monday, December 8th. Zacks Research lowered Amphastar Pharmaceuticals from a "strong-buy" rating to a "hold" rating in a research note on Friday, November 14th. Finally, Bank of America boosted their price target on Amphastar Pharmaceuticals from $28.00 to $32.00 and gave the company a "neutral" rating in a report on Tuesday, August 26th. Two equities research analysts have rated the stock with a Buy rating and six have issued a Hold rating to the stock. According to data from MarketBeat.com, the stock currently has a consensus rating of "Hold" and a consensus price target of $31.00.
Check Out Our Latest Analysis on Amphastar Pharmaceuticals
About Amphastar Pharmaceuticals
(
Get Free Report)
Amphastar Pharmaceuticals, Inc, a bio-pharmaceutical company, develops, manufactures, markets, and sells generic and proprietary injectable, inhalation, and intranasal products in the United States, China, and France. It offers BAQSIMI, a nasal spray for the treatment of severe hypoglycemia; Primatene Mist, an over-the-counter epinephrine inhalation product for the temporary relief of mild symptoms of intermittent asthma; Enoxaparin, to prevent and treat deep vein thrombosis; REXTOVY and Naloxone for opioid overdose; Glucagon for injection emergency kit; and Cortrosyn, for use as a diagnostic agent in the screening of patients with adrenocortical insufficiency.
See Also
This instant news alert was generated by narrative science technology and financial data from InsiderTrades.com in order to provide readers with the fastest and most accurate reporting. Please send any questions or comments about this story to [email protected].
